Gilead, OSI deal

OSIP will acquire GILD’s oncology business for up to $200 million. The deal includes GILD’s cancer

Read the full 164 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE